Substituted isoindolines as PI3K-alpha inhibitors
US12219327B2 · kind B2 · utility
0Cited by
0References
6Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 9, 2023 |
| Grant date | Feb 4, 2025 |
| Priority date | — |
| Expiry date | Jul 2, 2043 |
Classification
- Technology area (CPC H)Electricity
- CPC primaryH04R2225/55
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3K-α enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3K-α signaling with the compounds and compositions of the disclosure.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.